StockWatch
·
HomeLiveReports
Filing
Q3

Ami Organics Ltd

ACUTAASFY2528 Jan 2025
Revenue+11.4%
Net Profit+21.0%
OPM19.88%

P&L

Quarterly Consolidated

Revenue
+11.4%274.99
Expenditure
+4.0%213.32
Net Profit
+21.0%45.45
NPM 16.43%+11.6%EPS ₹11.35+21.0%

vs Q2 FY25

Ami Organics Limited Reports 65.2% YoY Growth in Q3FY25 Revenue from Operations

28 Jan 2025 · 28 Jan 2025, 11:55 pm

Summary

Ami Organics Limited, a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, announced a 65.2% year-on-year growth in Q3FY25, achieving Rs. 275 crore in revenue from operations. The gross margin for the quarter improved to 46.2% and EBITDA for the quarter came at Rs. 687 mn, up 159.0% YoY.

Key Highlights

  1. 1

    Revenue from operations for Q3FY25 grew by 65.2% YoY to Rs. 2,750 mn

  2. 2

    The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ

  3. 3

    EBITDA for the quarter came at Rs. 687 mn up 159.0% YoY compared to Rs. 265 mn in Q3FY24

  4. 4

    EBITDA margin for the quarter was at 25.0% as compared to 15.9% in Q3FY24

  5. 5

    PAT for the quarter was Rs. 454 mn up 155.1% as compared to PAT of Rs. 178mn in Q3FY24

  6. 6

    The PAT margin for the quarter was at 16.5% up 582 bps YoY and 130 bps QoQ

  7. 7

    Export for the quarter at 76%; domestic business at 24%

Management Comments

M

Mr. Naresh Patel

I am delighted to share that in the first nine months of FY25, we achieved revenue of Rs. 698 crore, nearly equalling the revenue from operations of the entire previous financial year. In Q3FY25 alone, we delivered an impressive 65.2% year-on-year growth, achieving Rs. 275 crore in revenue from operations. This performance was driven by a strong ramp-up in our CDMO business and consistent growth in advanced pharmaceutical intermediates. Our pipeline of CDMO projects is progressing well, with several initiatives nearing commercialization by FY26, solidifying the foundation for sustained long-term growth. Ongoing discussions with innovators and partners remain highly encouraging, and we are confident that the CDMO segment will see exponential growth in the coming years. With improved visibility for Q4, I am pleased to revise our FY25 growth guidance upward from 30% to 35%.

Informational and educational content only. Not investment advice.